Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-10-03
2006-10-03
Spector, Lorraine (Department: 1646)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387300, C530S387700, C530S388100, C530S388800, C424S143100, C424S155100
Reexamination Certificate
active
07115717
ABSTRACT:
Anti-TRAIL-R1 and R2 antibodies or functional fragments thereof, having at least one property selected from the following (a) to (c) of:(a) having activity to induce apoptosis in carcinoma cells expressing TRAIL-R1 and/or TRAIL-R2;(b) not having effect on normal human cells expressing TRAIL-R1 and/or TRAIL-R2; and(c) not inducing human hepatocyte toxicity.
REFERENCES:
patent: 6072047 (2000-06-01), Rauch et al.
patent: 6342369 (2002-01-01), Ashkenazi
patent: 6461823 (2002-10-01), Ni et al.
patent: 6872568 (2005-03-01), Ni et al.
patent: 2002/0155109 (2002-10-01), Lynch
patent: 2004/0180049 (2004-09-01), Ashkenazi et al.
patent: 10-327878 (1998-12-01), None
patent: WO 98/35986 (1998-08-01), None
patent: WO 98/41629 (1998-09-01), None
patent: WO 98/46643 (1998-10-01), None
patent: WO 98/51793 (1998-11-01), None
patent: WO 99/37684 (1999-07-01), None
patent: WO 96/64461 (1999-12-01), None
patent: WO 00/66156 (2000-11-01), None
patent: WO 99/37684 (2000-12-01), None
patent: WO 01/19861 (2001-03-01), None
patent: WO 01/83560 (2001-11-01), None
patent: WO 02/079377 (2002-10-01), None
patent: WO 02/085946 (2002-10-01), None
patent: WO 03/038043 (2003-05-01), None
patent: WO 03/042367 (2003-05-01), None
Silberstein et al., Relationship of variable region genes expressed by a human B cell lyphoma secreting pathologic anti-PR2 erythrocyte autoantibodies, J. Exp. Med., 169:1631-1643, May 1989.
Kazuma Tomizuka et al., “Double trans-chromosomic mice: Maintenance on two individual human chromosome fragments containing lg heavy and γ loci and expression of fully human antibodies”, PNAS, vol. 97, No. 2, Jan. 18, 2000, pp. 722-727.
Anan Chuntharapai et al., “Isotype-Dependent Inhibition of Tumor Growth in Vivo by Monoclonal Antibodies to Death Receptor 4”, The Journal of Immunology, vol. 166, pp. 4891-4898.
Kimihisa Ichikawa et al., “Tumoricidal Activity of a Novel anti-human DR5 Monoclonal Antibody without Helptocyte Cytotoxicity”, Nature Medicine, vol. 7, No. 8, Aug. 2001, pp. 954-960.
Thomas S. Griffith et al., “Functional Analysis of TRAIL Receptors Using Monoclonal Antibodies”, The Journal of Immunology, 1999, vol. 162: 2597-2605.
Kataoka Shiro
Mori Eiji
Kaufman Claire M.
Kirin Beer Kabushiki Kaisha
Spector Lorraine
LandOfFree
Anti-TRAIL-R antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-TRAIL-R antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-TRAIL-R antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3626094